Thus, while modulation of TRM survival through IL-15, TGF-β, or IL-4 pathways represents a conceptual curative strategy for rapid-onset ACD, its clinical feasibility and safety remain uncertain and require cautious investigation in human trials. The gene discussed is TGFB1; the disease is granular corneal dystrophy type II.